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Abstract
Using multicistronic expression technology we generated a stable Chinese hamster ovary (CHO) cell line (MG12)
expressing a model secreted heterologous glycoprotein, the secreted form of the human placental alkaline
phosphatase (SEAP), and bcl-2, best known as an apoptosis inhibitor, in a tetracycline-repressible dicistronic
configuration. In batch cultivations in serum-containing medium, MG12 cells reached twice the final viable cell
density when Bcl-2 was overexpressed (in the absence of tetracycline) compared to MG12 populations cultured
under tetracycline-containing conditions (bcl-2 repressed). However, bcl-2-expressing MG12 cells showed no
significant retardation of the decline phase compared to batch cultures in which the dicistronic expression unit
was repressed. Genetic linkage of bcl-2 expression with the reporter protein SEAP in our multicistronic construct
allowed online monitoring of Bcl-2 expression over an extended, multistage fixed-bed bioreactor cultivation. The
cloned multicistronic expression unit proved to be stable over a 100 day bioreactor run. CHO MG12 cells in the
fixed-bed reactor showed a drastic decrease in the release of DNA into the culture supernatant under conditions of
reduced tetracycline (and hence derepressed SEAP and bcl-2 overexpression). This observation indicated enhanced
robustness associated with bcl-2 overexpression, similar to recent findings for constitutive Bcl-2-overexpressing
hybridoma cells under the same bioprocess conditions. These findings indicate, in these serum-containing CHO
cell cultures, that overexpression of Bcl-2 results in desirable modifications in culture physiology.
Nomenclature
ci = substrate or product concentration in
the reactor (mmol l−1)
ci0 = substrate or product concentration in
the feed (mmol l−1)
qi = substrate uptake or metabolite produc-
tion rate per volume conditioning ves-
sel (mmol l−1 h−1)
qi;FB = substrate uptake or metabolite produc-
tion rate per volume fixed-bed (mmol
l−1FB h−1)
VFB = volume of the fixed-bed (l)
VC = volume of the conditioning vessel (l)
DFB = dilution rate related to the fixed-bed
volume (d−1)
D = dilution rate related to the conditioning
vessel (d−1)
t = time (d)
Introduction
Chinese Hamster ovary cells are the most import-
ant animal cell hosts for industrial manufacturing of
protein pharmaceuticals. Understanding of the mecha-
nism and kinetics for both cell growth and cell death
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in various culture systems is of central importance for
the optimization of recombinant protein production.
While the parameters for cell growth are well estab-
lished for many production cell lines and bioreactor
conditions, prevention of cell death has only recently
attracted much interest in the bioengineering com-
munity (de la Broise et al., 1991; Duval et al., 1991;
Al-Rubeai et al., 1995; Cotter and Al-Rubeai, 1995;
Mastrangelo and Betenbaugh, 1998; Dickson, 1998).
Contemporary basic research has revealed an in-
trinsic, genetically determined program which com-
mits a cell to die in response to physiological con-
straints such as serum, nutrient and oxygen depletion.
Programmed cell death, or apoptosis, is a complex and
active energy-dependent biochemical network con-
trolled by an enzymatic cascade and intracellular sig-
nal transduction circuits (Hale et al., 1996; Cohen,
1997; Newton and Strasser, 1998; Fussenegger and
Bailey, 1998; Fussenegger et al., 1998c). Cell death
by apoptosis differs from ‘classical’ cell death or nec-
rosis, whereby the cells die by total disintegration
and release the cellular content into the surrounding
area. Apoptosis instead involves distinct morpholo-
gical characteristics such as volume loss by condensa-
tion of chromatin (accompanied by DNA breakdown)
and cytosplasmatic organelles, disintegration of the
nucleus, and the bulging out of membrane blebs (ap-
optotic bodies) containing cytoplasmatic components.
In vivo these apoptotic bodies are phagocytosed by the
surrounding tissue, but under cell culture conditions
they eventually lyse by a process called secondary
necrosis.
Hybridoma cells have been reported to be very
sensitive to apoptosis, particularly when they have
reached their final cell density and enter the decline
phase (de la Broise et al., 1991; Mercille and Massie,
1994). Additionally, cell culture additives which arrest
cell growth were shown to enhance antibody produc-
tion of hybridoma cells but also to induce apoptosis
(Suzuki and Ollis, 1990; Franek and Dolnikova 1991;
Al-Rubeai et al., 1992; Terada et al., 1997; Franek et
al., 1998). Given the negative effect of programmed
cell death for hybridoma culture productivity these cell
types became the paradigm for apoptosis suppression
by metabolic engineering.
Bcl-2 is the first key negative regulator of apop-
tosis which has been described (Tsujimoto and Croce,
1986). Since its discovery, many homologous Bcl-2-
like family members have been identified, some of
which inhibit (Bcl-2, Bcl-xL, Bcl-w, A1, Mcl-1) or
promote programmed cell death (Bax, Bak, Bad, Bcl-
xS) (Adams and Cory, 1998; Fussenegger and Bailey,
1998; Newton and Strasser, 1998). All of these bcl-2-
like proteins form a complex rheostat-like intrafamily
network in which the sum of the positive and nega-
tive interactions determines the apoptotic response to
physiological stresses. Bcl-2 is intimately linked with
the cell cycle since the central cell-cycle regulator and
tumor suppressor gene p53 acts as higher order regu-
lator of apoptosis by repressing bcl-2 expression while
inducing bax (Ko and Prives, 1996). Although the role
of Bcl-2 in the signalling network seems to be well
established at the molecular level, the target genes
and mechanisms by which Bcl-2 effects apoptosis sup-
pression remain somewhat obscure. Linked with the
remaining secrets of Bcl-2 is its subcellular localiza-
tion to nuclear membrane as well as to the membranes
of the endoplasmatic reticulum and the mitochondria,
a feature which bcl-2 shares with bcl-xL (Chen-Levy
and Cleary, 1990; De Jong et al., 1992; Adams and
Cory, 1998; Thornberry and Lazebnik, 1998). Al-
though the significance of the membrane localization
to cell death has been unclear, there is now good evid-
ence that the mitochondria may play a pivotal role in a
cell death pathway (Green and Reed, 1998). The con-
nection between the anti-apoptotic function of Bcl-2
and Bcl-xL and their localization at the mitochondrial
membrane was recently suggested to reside in a block
of cytochrome C release from mitochondria (Kluck et
al., 1997; Yang et al., 1997; Kharbanda et al., 1997;
Adams and Cory, 1998; Green and Reed, 1998). The
release of cytochrome C has recently been shown to
be sufficient for the activation of initiating procaspases
such as caspase-9 or caspase-3 which in turn activate a
nuclear endonuclease responsible for DNA fragment-
ation as well as PAK2, a kinase which appears to be
required for plasma membrane blebbing and the form-
ation of apoptotic bodies (Liu et al., 1997; Rudel and
Bokoch, 1997).
Bcl-2-based metabolic engineering has been suc-
cessfully used to suppress apoptosis in many cell lines
in response to various chemical, genetic, biochem-
ical and viral apoptosis-inducing conditions (Balajthy
et al., 1997; Camilleri-Broet et al., 1998; Chung et
al., 1997; He et al., 1996; Mastrangelo and Beten-
baugh, 1998; Meikrantz et al., 1998; Reynolds et al.,
1996a, b; Zhang et al., 1995). Also, high level ex-
pression of human bcl-2 resulted in better survival of
mouse myeloid cells in the absence of growth factors
(Tsujimoto, 1989; Vaux et al., 1988). Deregulated
bcl-2 expression prolonged survival of growth factor-
deprived hemopoietic cell lines (Nunez et al., 1990)
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and protects human B cells from a variety of physiolo-
gical stress conditions (Tsujimoto, 1989; Miyashita
and Reed, 1992). Furthermore, Bcl-2 was extremely
successful in suppressing apoptosis in hybridoma cell
cultures, leading sometimes to enhanced specific an-
tibody production (Itoh et al., 1995; Fassnacht et al.,
1998a) or enabling production technology by the addi-
tion of growth-inhibiting cell culture additives (Terada
et al., 1997). However, bcl-2 may not be a universal
apoptosis inhibitor, and its potential and function may
vary among different cell lines. For example, Bcl-
2 showed no apoptosis-suppressing activity in NSO
myeloma cells (Murray et al., 1996).
In contrast to hybridoma cells, cytostatic culture
technology implemented in CHO cells by the con-
ditional overexpression of p27 or p21 lead to G1-
phase-specific growth arrest and increased heterolog-
ous protein production, but the induction of apoptosis
was not observed in the arrested CHO cell cultures
(Fussenegger et al., 1997; Fussenegger et al., 1998b;
Mazur et al., 1998). However, CHO cells in batch
culture have been reported to die almost exclusively
via apoptosis (Moore et al., 1995). In this study, we
combine regulated gene expression and multicistronic
expression technology to assess the effect of Bcl-2 in
CHO cells under batch culture conditions and in fixed-
bed reactors in an absolutely isogenic background and
in the absence of chemical, genetic and biochemical
apoptosis inducers against most of which Bcl-2 has
previously been reported to provide some protection
(Balajthy et al., 1997; Camilleri-Broet et al., 1998;
Chung et al., 1997; He et al., 1996; Meikrantz et al.,
1988; Reynolds et al., 1996a, b; Zhang et al., 1995).
Regulated expression technology eliminates se-
condary effects of clonal variation commonly en-
countered by classical polyclonal or single-clone ana-
lyses. Furthermore, isogenic metabolic engineering
assessments achieved by regulated gene expression
reduces genetic drift in long-term, reactor cultivations.
Materials and methods
Cell culture and transfection
For the generation of stable cell lines Chinese ham-
ster ovary cells (CHO-K1, ATCC: CCL 61) were
cultured in FMX-8 medium (Dr. F. Messi Cell Cul-
ture Systems, Switzerland) supplemented with 10%
fetal calf serum (FCS, Boehringer Mannheim, Lot
Nr. 14713602). The cell line XMK1-9 is a deriv-
ative of CHO-K1 which constitutively expresses the
tetracycline-responsive transactivator tTA (Fusseneg-
ger et al., 1997; Fussenegger et al., 1998b; Mazur et
al., 1998). XMK1-9 was cultured in FMX-8 medium
that also contained 400 g/ml of G418 (GIBCO BRL,
Life Technologies). For repression of the tetracycline
regulatable promoter PhCMV−1 (Gossen and Bujard,
1992), 2 g/ml of tetracycline (Sigma) was used. For
high efficiency transfection, a modified CaPO4 pro-
tocol was used (P. Umaña et al., in preparation). For
batch cultures and cultivation in the fixed-bed reactor a
1:1 mixture of Iscove’s MDM and Ham’s F12 (GIBCO
BRL, Life Technologies) supplemented with 2 mmol
l−1 L-glutamine (GIBCO BRL, Life Technologies),
2 g l−1 NaHCO3, 0.01% PEG, 50 mmol l−1 eth-
anolamine, 6 mg l−1 puromycin, 400 mg l−1 G418
(Calbiochem) and 3% (v/w) horse serum (GIBCO
BRL, Life Technologies; Lot Nr. 30A1045D) was
used. The trypan blue dye exclusion method was used
to distinguish viable from dead cells on the basis of
membrane integrity. Cells that exclude trypan blue
have an intact membrane and are viable (MI) whereas
cells which take this dye up show a disrupted mem-
brane which is indicative of dead cells. The membrane
intact index was calculated as the ratio of cells with an
intact membrane to total cell number (Simpson et al.,
1997; Fassnacht et al., 1998a).
The eukaryotic expression vector pSFFVNeo-bcl2
encoding the human anti-apoptosis factor Bcl-2 has
been reported by Tsujimoto and Croce (1986). bcl-2
was released by restriction of pSFFVNeo-bcl2 with
EcoRI and was subsequently cloned into the EcoRI
site of pBluescriptcircR II SK− placing this gene un-
der the control of the lacZ promoter to give plas-
mid pMF137. bcl-2 was excised from pMF137 as a
NotI/SalI fragment and ligated to the corresponding
sites of pSBC2 resulting in pMF147 (Dirks et al.,
1993).
Enzymatic assays
The SEAP concentration in the culture supernatant
was determined by measuring the kinetics of the hy-
drolysis of p-nitrophenolphosphate (Sigma) for 10 min
at 30 C and 405 nm in a 96-well multiplate reader
(Spectra Thermo, SLT Laborinstrumente)(adapted
from Berger et al., 1988). 80 l of sample were mixed
with 100 l of SEAP buffer (20 mM L-homoarginine,
2 M diethanolamine, 1 mM MgCl2, pH 9.8). 20 l
of substrate was added immediatelly prior to measure-
ment. SEAP activity was measured in units per liter.
One unit is defined as the amount of SEAP which
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Figure 1. Construction of the dicistronic expression vector pMG12. pMG12 was fused from two monocistronic expression vectors pMF111 and
pMF147 and contains a dicistronic expression unit under control of the tetracycline-repressible promoter PhCMV−1. The dicistronic expression
unit encodes the model product gene seap and the survival gene bcl-2 which are transcribed into a single mRNA. Both genes are separated by
the internal ribosomal entry site (IRES) which mediates cap-independent translation initiation of the second, bcl-2 encoding cistron and enables
simultaneous and coordinated expression of seap and bcl-2.
hydrolyze 1 nmol of p-nitrophenylphosphate per min.
A concentration of 1 mU per liter corresponds to an
increase of 0.028 1E per minute given a liquid height
of 0.7 cm (Berger et al., 1988).
Glucose and lactate were determined with a YSI-
Analyzer 2700 (YSI, U.S.A.). Glutamine and am-
monia were analyzed enzymatically according to
the manufacturer’s protocols (Boehringer Mannheim,
Germany).
Western blot analysis
Tetracycline-responsive expression of bcl-2 coordin-
ated with SEAP expression in MG12 cells was con-
firmed by Western Blot analysis. 106 cells were de-
tached from the culture vessel, washed twice with
PBS and resuspended in lysis buffer (1% IGEPAL
(Sigma, CA-630), 150 mM NaCl, 50 mM Tris, pH
7.5, 1 mM EDTA, 1 mM PMSF, 21 g/ml aprotinin,
10 g/ml leupeptin) for 30 min on ice (adapted from
Behrens et al, 1994). The cells were then sonified
twice for 1 min on ice before the cell lysate was
centrifuged at 14 000  g for 10 min at 4 C. The
protein concentration of the supernatant was determ-
ined using a BCA protein assay (Pierce) according
to the manufacturer’s protocol. Equal protein concen-
trations were applied on a 12.5% polyacrylamide-SDS
gel and the proteins were subsequently blotted onto ni-
trocellulose membranes using a Bio-Rad electroblotter
(Sambrook et al., 1989). The blot was developed
using the primary monoclonal antibody against hu-
man Bcl-2 (purified mouse monoclonal anti-bcl-2 IgG
lot# 9612009; Ancell Corp. (Bayport, MN, U.S.A.)
and the ECL Western Blot kit (Amersham) using the
manufacturer’s suggested protocol.
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Table 1. Plasmids used in this study
Plasmid Description Reference or source
pTBC1 Cloning vector containing the tetracycline-regulatable promoter PhCMV−1 Dirks et al., 1994
pSBC2 Cloning vector Dirks et al., 1993
pSFFVNeo-bcl2 pSFFV-Neo expression vector containing the human bcl-2 gene as an EcoRI fragment Tsujomoto and Croce, 1986
pMF111 pTBC1containing seap as EcoRI/HindIII fragment of pSBC2-SEAP Fussenegger et al., 1997a
pMF137 pSSFNeo-bcl2 was restricted with EcoRI and the bcl-2 containing fragment was cloned
into pBluescriptr II SK−(EcoRI)
Fussenegger et al., 1998
pMF147 pSBC2 containing the bcl-2 gene as NotI/SalI fragment of pMF137 This work
pMG12 Dicistronic tet-regulatable SEAP-Bcl-2 expression vector; NotI/VspI fusion of pMF137
and pMF147
This work
Measurement of the DNA concentration in the culture
supernatant
Since dead and damaged cells release their chromo-
somal DNA, the time course of DNA concentration in
the supernatant is indicative of the extent of cell death
(Sramkova et al., 1997). The DNA concentration in the
cell culture supernatant was determined by Hoechst-
33258 (Sigma) staining. 100 g of Hoechst-33258
were dissolved in Ca2C- and Mg2C-free PBS. 13 l
of this stock solution was added to 1050l Tris-buffer
(250 mmol l−1, pH 8) and 250 l of culture super-
natant. The fluorescence of the DNA-fluorochrome
complex, excited at 353 nm, was measured at 460 nm
on a spectrofluorometer (Shimadzu, RF-540). The
DNA concentration was determined using a calibra-
tion curve.
Apoptosis assays
The terminal stage of apoptosis includes degradation
of chromosomal DNA at nucleosomal intervals (‘DNA
ladder’. Therefore, chromosomal DNA of CHO cells
was isolated as follows: 3.5  105 cells were incub-
ated in 100 l PBS containing 100 g DNAse-free
RNAse A (Boehringer Mannheim) for 1 h at room
temperature. The DNA was extracted twice using first
50 l phenol and 50 l of a chloroform/iso-amylic
alcohol mixture (24:1) and subsequently 100 l of
the chloroform/iso-amylic alcohol mixture (24:1). The
DNA in the aqueous supernatant was then precipitated
with 10 volumes isopropanol and 1 volume sodium
acetate (3 M, pH 5.2) for 10 min at –20 C. The
precipitated DNA was collected by centrifugation at
10 000  g for 15 min, the pellet was washed twice
with ice-cold 70% ethanol and resuspended in 20 l
water. In order to monitor the ladder-like degradation
of the DNA following induction of the cellular ap-
optosis program, the DNA was visualized by agarose
gel electrophoresis as described before (Sambrook et
al., 1989). Apoptosis was also quantified using an
ApoAlertTM CPP32/Caspase-3 assay kit (Clontech)
according to the manufacturer’s protocol.
Cultivations in the fixed-bed reactor
For extended cultivation of the CHO cell line MG12,
a fixed-bed reactor (Meredos, Germany) was used.
The fixed-bed reactor setup consists of a 1 liter con-
ditioning vessel and a 50 ml fixed-bed in which the
cells are immobilized on porous glass beads (3 to
5 mm in diameter (Siran, Schott, Germany)), a carrier
which proved to be particularly suitable for culti-
vation of suspendable cells such as transfectoma or hy-
bridoma as well as for adherent cells including CHO-
K1 (Sràmkovà et al., 1995; Lüdemann et al., 1996;
Pörtner et al., 1997). The fixed-bed is integrated in the
conditioning vessel which allows simultaneous tem-
perature control and maintenance of both subsystems
at 37 C by electrical heating. Between the fixed-bed
and the conditioning vessel, a closed medium circuit
is established with medium being pumped from the
conditioning vessel through the fixed-bed (axially) and
back into the conditioning vessel. The maximum su-
perficial flow velocity in the fixed-bed was constantly
kept below 0.9 mm s−1 to minimize cell washout from
the fixed-bed. This superficial flow velocity was de-
termined by dividing the volumetric flow rate by the
cross sectional area of the fixed-bed (20 cm2). The dis-
solved oxygen in the conditioning vessel (equipment
by Ingold, Germany) was maintained between 75 and
85% of air saturation by regulating the gassing rate.
pH was measured and automatically controlled by the
addition of CO2 to the air used for bubble aeration
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(electrode CPS11-1DA4GSA, Endress + Hauser, Ger-
many). Sampling and medium exchange during con-
tinuous operation were carried out in the conditioning
vessel.
For inoculation, the circulation between the con-
ditioning vessel and the fixed-bed was closed. The
cells were filled into a bottle which was connected to
the fixed-bed by a separate circulation loop. The cells
were then slowly pumped through the fixed-bed for ap-
proximately 2 h until the inoculation suspension in the
bottle became clear. The inoculation circuit was then
closed and the circulation between the conditioning
vessel and the fixed-bed was re-opened. The fixed-
bed was inoculated with 1106 cells per ml fixed-bed
which corresponds to a total cell number of 5107
cells.




D D .ci0 − ci/C qi (1)
D is the dilution rate of medium in the conditioning
vessel, ci the substrate or product concentration, ci0
the substrate or product feed concentration and qi in-
dicates the production rate of component i per volume
conditioning vessel.
The dilution rate and the substrate consumption or
metabolite production rates per volume fixed-bed are
defined in Equations (2) and (3). VC is the volume of









Using Equations (1), (2) and (3), the following Equa-
tions (4) are obtained in case of a steady-state assum-
ing ideal mixing in the conditioning vessel.
dci
dt
WD 0) D .ci − ci0/C q

i
DFB .ci − ci0/C qi;FB (4)
Results
Construction of a dicistronic, tetracycline-regulatable
expression unit encoding the model product protein
SEAP and the survival factor Bcl-2
Dicistronic expression systems enable simultaneous
and coordinated expression of two independent genes
from a single promoter. While the translation of the
first cistron is mediated by classical cap-dependent
translation, translation-initation of the second cistron
relies on a genetic element of polioviral origin the
internal ribosomal entry sites (IRES). By VspI/NotI-
mediated fusion of the two independent expression
vectors pMF111, encoding the model product gene
the human placental alkaline phosphatase (SEAP;
Fussenegger et al., 1997) and pMF147, encoding the
Bcl-2, pMG12 was generated which harbors SEAP-
bcl-2 as a single dicistronic expression unit under con-
trol of the tetracycline-repressible promoter PhCMV−1
(Figure 1). Activity as well as tetracycline-repressible
expression of pMG12 was tested by transient trans-
fection of this dicistronic expression vector into the
CHO-K1 derivative XMK1-9 which was previously
engineered to constitutively express the tetracycline-
responsive transactivator (tTA; Fussenegger et al.,
1997). In all cases the expression of SEAP and bcl-2
in transfected CHO populations was strictly correl-
ated and tightly repressed by the addition of the ex-
ternal stimulus tetracycline (Tetoff) as confirmed by
enzymatic SEAP assays and bcl-2-directed immuno-
fluorescence (data not shown).
Construction of a CHO cell line which stably
expresses the dicistronic, tetracycline-regulatable
SEAP-bcl-2 expression unit
Plasmid pMG12 was cotransfected with pPur, an ex-
pression vector encoding resistance against the anti-
biotic puromycin, into XMK1-9 overexpressing the
tetracycline-responsive transactivator. A mixed pop-
ulation was selected in 13 mg l−1 puromycin and
single clones were then generated by two subsequent
rounds of limiting dilution. Since constitutive expres-
sion of both genes was shown to have no deleterious
effects in various cells (Huang et al., 1997; Terada et
al., 1997; Fussenegger et al., 1998a), the selection
procedure was carried out in the absence of tetra-
cycline in the culture medium, and thus under full
expression of the dicistronic expression unit. Expres-
sion of the dicistronic expression unit enabled easy,
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SEAP-based detection of cells harboring pMG12 dur-
ing the entire selection procedure. Several individual
pMG12-containing clones were generated and tested
for tetracycline-mediated repression of the dicistronic
expression unit. As the tightness of repression of the
dicistronic expression unit minimizes or largely ex-
cludes the influence of host promoter and/or enhancer
elements on the dicistronic expression unit, the CHO
cell clone MG12, which showed a slope of <10−4 in
phosphatase kinetics, was selected for further invest-
igations. Due to the dicistronic nature of the SEAP-
bcl-2-encoding expression unit, bcl-2 expression was
also highly tetracycline-regulatable as shown by West-
ern blot analysis of MG (Figure 2) which was strictly
coordinated with SEAP expression (data not shown).
Batch cultivations of MG12
For investigation of the influence of Bcl-2 expression
on CHO cell culture processes, MG12 was culti-
vated in the presence (MG12Ctet ; bcl-2 repressed) and
absence of tetracycline (MG12−tet ; bcl-2 overexpres-
sion). Since MG12 cells were typically propagated
in the absence of tetracycline MG12Ctet populations
were precultured for 5 days in tetracycline-containing
medium to avoid the adaptation to the repressed state
(SEAP-Bcl-2 off) to take place during the batch ex-
periment. This batch cultivation was extended to 18
days to include exponential growth (ideal growth con-
ditions) as well as the death phase (sub-optimal growth
conditions). During the first three days of cultiva-
tion, both cultures MG12Ctet and MG12−tet showed
a similar specific growth rate to a viable (membrane
intact) cell density of 3:5105 cells ml−1 (Figure 3A).
However, whereas MG12Ctet ceased to grow expo-
nentially and reached a final viable cell density of
5:5105 cells ml−1, the bcl-2-expressing MG12−tet
culture continued to grow exponentially until day 6,
finally reaching a viable cell density of 1:2106, more
than twice as much as MG12Ctet populations (Fig-
ure 3A). In order to exclude a potential negative effect
of tetracycline on the growth behavior, CHO-K1 as
well as its tTA-expressing derivative XMK1-9 were
grown in the presence and absence of tetracycline
with no difference in the growth behavior of both cell
lines (data not shown). Furthermore, regulation effect-
ive concentrations of tetracycline in the cell culture
medium are generally accepted not to influence cell
physiology (Gossen and Bujard, 1992).
After both cell populations (MG12Ctet and
MG12−tet) had reached their final cell densities, they
started to die (Figure 3B). A significant difference
in the decline phases of MG12Ctet and MG12−tet
could not be detected (Figure 3B). Electrophoresis
of chromosomal DNA isolated from MG12Ctet and
MG12−tet cells at day 14 showed discrete bands of
180 bp multimers which is a consequence of the
chromosomal breakup at nucleosomal intervals by a
specific endonuclease typically active in the apop-
totic cell death program (Figure 4; Adams and Cory,
1998; Newton and Strasser, 1998). Furthermore, the
ApoAlertTM assay (Clontech) failed to detect signific-
ant differences in the levels of the initiator caspase-3
in MG12Ctet and MG12−tet cultures suggesting that
bcl-2-mediated apoptosis protection is not detectable
under conditions studied here.
Due to the dicistronic nature of the SEAP-bcl-2 ex-
pression construct, the coordinated expression of both
genes allows bcl-2 expression to be monitored via con-
comitant SEAP expression and secretion. The SEAP
activity measured in the culture supernatant confirms
expression of the dicistronic expression unit in the
absence of tetracycline and repression in the pres-
ence of tetracycline over the entire cultivation period,
respectively (Figure 3C).
Figure 5 shows the glutamine/ammonia as well
as the glucose/lactate time courses of MG12Ctet
and MG12−tet populations over the entire cultiva-
tion period. Whereas bcl-2-expressing populations
had already metabolized the glutamine pool at day 6
MG12Ctet cells were running out of glutamine only at
day ten (Figure 5). In spite of the more rapid glutam-
ine consumption, Bcl-2-expressing cultures had lower
ammonia levels during most of the first 8 days of
culture. Glucose utilization profiles were very similar
for both cultures. Lactate was first produced and
then consumed. Lactate was produced more rapidly
by MG12Ctet cultures, attaining a maximal lactate
concentration almost twice as high compared to the
MG12−tet cultures. The reason for the lower maximal
lactate concentration of the Bcl-2-expressing cell line
is that glutamine limitation and consumption of lact-
ate started on day 5. For the other cell state (bcl-2
repressed) glutamine became limited only beyond day
10 and more lactate could therefore accumulate.
Fixed-bed cultivations of MG12
In order to assess the effect of bcl-2 on CHO cells
under conditions of a high cell density, perfused cul-
ture system, and to study the long-term stability of
multicistronic expression technology, MG12 was cul-
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Bcl-2
- tet +tet 
26 kD a
Figure 2. Western blot analysis of Bcl-2 expression of MG12 grown in the absence (–tet) and the presence (+tet) of tetracycline. Expression of
Bcl-2 (26 kDa) is undetectable in the presence of tetracycline in the cell culture medium and Bcl-2 protein is overexpressed in its absence.
tivated in a fixed-bed reactor. Following inoculation
into tetracycline-free culture medium the fixed-bed re-
actor was run in batch mode for 4 days until glucose
was nearly consumed. Thereafter, continuous opera-
tion of the fixed-bed reactor was initiated. In order
to impose further stress on the cells, the cultivation
was performed at a low dilution rate (DFB) of 3 d−1.
In the tetracycline-free medium SEAP and bcl-2 are
fully expressed and the increase in SEAP activity dur-
ing the first 40 days may indicate increase in cell
density which correlates with decreasing glutamine
and glucose concentrations (data not shown) (Fig-
ure 6). A first steady-state appeared after 45 days of
continuous operation. On day 61, the culture feed me-
dium was changed to contain 2 mg l−1 tetracycline
which induced a decrease in SEAP activity, and a new
steady-state for all parameters was reached on day 86
(Figure 6). The gradual decrease in SEAP activity dur-
ing the culture period between day 60 and day 80 is
due to the low wash-out of this protein from the reactor
given the fixed-bed reactor configuration and setup.
The steady-state concentrations and the specific
substrate uptake or metabolite production rates per
volume fixed-bed of glucose, lactate, glutamine, am-
monia, the SEAP activity and the DNA content are
shown in Table 2 for tetracycline-free (day 45 to 60)
and tetracycline-containing cultivation periods (day
86–100). In addition, DNA release kinetics is shown in
Figure 6. Apart from the DNA content (and of course
the SEAP activity), there is no significant difference
in key culture parameters between both cultivation
conditions which suggest a high stability of the cell
line MG12 and the fixed-bed reactor set-up over long
cultivation periods. Due to the different conditions
of batch and fixed-bed cultivations the relative meta-
bolic production and consumption rates of MG12Ctet
and MG12−tet populations can not be directly com-
pared. For example, in batch cultivation lactate was
not the final metabolite, but can be consumed under
unfavorable condition such as glutamine limitation.
Since dead and damaged cells release their DNA,
the DNA concentration in the culture supernatant is in-
dicative of cell death, comparable to the release of the
lactate dehydrogenase (LDH) (Sramkova et al., 1997).
Therefore, the rate of DNA accumulation in the culture
supernatant correlates with the death rate of cultured
cells. MG12Ctet with repressed bcl-2 expression show
8010% higher DNA accumulation rate compared to
MG12−tet cells, suggesting a protective effect of bcl-2
on the death rate under unfavorable conditions in the
fixed-bed ractor. Similar results have been found for a
bcl-2 expressing hybridoma cell line, where a decrease
in the cell turn-over led to higher antibody yields in the
fixed-bed system (Fassnacht et al., 1998b).
Discussion
Conditionally-regulated expression of endogenous
genes is a desirable goal in stable cell line and trans-
genic animal systems, as well as in clinical gene
therapy. Although regulated gene expression techno-
logy is a well established tool in contemporary basic
research since it simplifies and greatly speeds up func-
tional genomic research by enabling the assessment
of gene function in a strictly isogenic background,
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Figure 3. Batch cultivation of MG12 in tetracycline-free ( ) and tetracycline-containing (#) medium. Viable cell density (cells with intact
membrane, MI) (A), membrane intact index (B) and SEAP production (C) was assessed during a cultivation priod of 18 days. Bcl-2-expressing
MG12 cells grow to double the final cell density as isogenic MG12 populations with repressed dicistronic expression unit (A). However, Bcl-2
overexpression provides little or no protective effects during the decline phase of both cultures starting at day 14 (B). The expression of the
dicistronic expression unit can be monitored online by measuring the activity of the secreted reporter protein SEAP which correlates with
expression of Bcl-2 (C).
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Figure 4. Electrophoretical analysis of chromosomal DNA isolated from MGg12 cells grown in batch cultures in the presence (MG12Ctet )
and in the absence of tetracycline (MG12−tet ). Both cell populations show the DNA laddering characteristic of apoptosis caused by
intranucleosomal strand cleavage by an apoptosis-specific nuclease. M represents a DNA size marker.
Table 2. Culture supernatant concentrations and consumption or production rates
per volume fixed-bed of the steady-state fixed-bed data (calculated by using Equa-
tions (1)–(3))
induced Bcl-2 and SEAP repressed Bcl-2 and SEAP
(45–60 days) (86–100 days)
cglucose [mmol l−1] 0.35 0.3
clactate [mmol l−1] 20 15
cglutamine [mmol l−1] 0.15 0.15
cammonia [mmol l−1] 3.1 3.3
cSEAP [units l−1] 0.69 0.19
cDNA [mg l−1] 0.75 1.4
qFB;glucose [mmol lFB−1 h−1] –2.2 –2.2
qFB;lactate [mmol lFB−1 h−1] 2.5 1.9
qFB;glutamine [mmol lFB−1 h−1] –0.42 –0.42
qFB;ammonia [mmol lFB−1 h−1] 0.39 0.41
qFB;SEAP [units lFB−1 h−1] 0.086 0.024
qFB;DNA [mg lFB−1 h−1] 0.094 0.17
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bioengineers discovered only recently the potential of
regulated gene expression for the expression of toxic
transgenes (Cook et al., 1997) or the development of
novel cytostatic bioprocesses for enhanced production
of heterologous proteins (Fussenegger et al., 1997;
Fussenegger et al., 1998b; Fussenegger et al., 1998c;
Mazur et al., 1998).
Classical metabolic engineering of industrially re-
levant cell lines often involves selection of cell clones
which stably and constitutively express the transgenes.
However, as the transfected transgenic information
is integrated into the host chromosome by illegiti-
mate recombination at random sites, the outcome of
classical metabolic engineering can depend signifi-
cantly on high clonal variations between generated
cell lines which complicates interpretation of specific
gene functions and engineering effects: (i) random in-
tegration of the transgene may result in disruption of
host chromosomal loci which could lead to secondary
effects unrelated to the metabolic engineering intent,
(ii) the chromosomal context at the integration site
may influence transgene expression, and (iii) multiple
integration of transgenes at different locations may
cause dosage effects, function as targets for secondary
recombinations or simply potentiate the problematic
genetic configurations stated above.
Several strategies have been developed to allevi-
ate clonal variation following metabolic engineering
including characterization of multiple clones, transi-
ent transfections, stable polyclonal populations and
targeted integration. Apart from targeted integration,
which requires complex pre-engineering and screen-
ing for appropriate integration sites (Karremann et
al., 1996), the transient transfection and polyclonal
population strategies certainly reduce unrelated effects
resulting from clonal variations, but they do not allow
long-term cultivations as the transgene is lost in a few
generations in transient transfection experiments and
mixed populations may change due to different growth
behavior of individual cell clones.
Regulated gene expression has the potential to al-
leviate most critical issues of clonal variations and
enables the metabolic engineering effector, here the
survival factor bcl-2, to be studied in a completely
isogenic background:
(i) complete repression of the transgene guarantees
the absence of host promoter/enhancer elements
influencing the heterologous expression unit;
(ii) assessment of two different cell states (expression
and repression of the gene of interest) in a strictly
isogenic background;
(iii) disruption of chromosomal target genes by integ-
ration of the gene of interest is normalized by
repressed configurations;
(iv) multiple integrations are still possible but regulated
expression system enforces coordinated behavior
of different loci. Therefore, regulated expression
of metabolic transgenes offers a straightforward
strategy to assess the potential of a candidate gene
for metabolic engineering.
Although apoptosis is a vital mechanism for multicel-
lular life (Raff, 1992; Von Boehmer, 1994) it is an
undesired phenomenon in biotechnological production
processes since premature cell death eliminates viable
cell population and hence production potential (Franek
and Dolnikova, 1991; Duval et al., 1991). Further-
more, because of the complex signalling pathways in-
volved in the induction of apoptosis, cell death signals
could be expected to rapidly spread within a culture
and affect the remaining healthy cell population.
One of the most important and intrinsic causes of
apoptosis in mammalian cell culture is the depriva-
tion of nutrients and special survival factors during the
course of cultivation. Recent studies suggest that de-
pletion of any amino acid can induce apoptosis and the
effect is greatest when there is a lack in essential amino
acids (Duval et al., 1991; Simpson et al., 1998). The
discovery of nutrient depletion-induced programmed
cell death stimulated sophisticated feeding strategies
as well as research on chemical cell culture additives
suppressing apoptosis. It has been demonstrated that
apoptotic hybridoma cultures could be rescued by the
addition of a single amino acid (Franek and Sramkova,
1996). However, although feeding strategies may suc-
cessfully retard the onset of apoptosis in hybridoma
and myeloma cell lines they do not necessarily en-
hance cellular productivity (Franek and Dolnikova,
1991). In fact heterologous protein productivity was
greatest in growth-arrested or slow growing cells and
growth-inhibitory strategies such as nutrient depriva-
tion and the addition of specific chemicals (thymidine
or hydroxyurea, TGF-; Suzuki and Ollis, 1990; Al-
Rubeai et al., 1992) have long ago been elaborated to
increase productivity of these cell lines.
However, not all cell lines respond by apoptosis to
nutrient deprivation. Some cell lines, including HeLa
and HL60 cells have been suggested to block cellular
proliferation following nutrient deprivation to repair
defects or await improvement of physiological con-
ditions rather than initiating programmed cell death
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Figure 5. Physiological parameters: glutamine (#/ ) and ammonia (/) (A) and glucose (#/ ) and lactate (/) (B) concentrations. MG12
cells were grown under conditions repressing (#/, presence of tetracycline) or inducing ( /, absence of tetracycline) coordinated bcl-2 and
SEAP expression. The bcl-2-expressing MG12 culture consumes glutamine faster and exhibits lower lactate concentrations.
(Perreaut and Lemmieux, 1993). The phenomenon
of G1-phase accumulation in response to apoptosis
induction in the cultured population has also been
observed in CHO cells (Moore et al., 1995). How-
ever, we recently showed that CHO cell engineered for
tetracycline-regulated expression of tumor suppressor
genes showed greatly enhanced heterologous protein
productivity under G1-arrested conditions without any
signs of apoptosis (Fussenegger et al., 1998b; Mazur
et al., 1998). It seems that in some cell lines apoptosis
may be repressed in the G1-phase or at least in some
stages of G1-phase, a cell-cycle phase which often
functions as recovery phase from a wide variety of
physiological insults before entering the cell division
program (Fussenegger et al., 1997; Fussenegger et al.,
1998b; Mazur et al., 1998).
Besides special feeding strategies and the addition
of anti-apoptotic medium additives, metabolic engin-
eering of key regulators of cellular survival pathways
has been used to prevent the induction of apoptosis
by physiological stresses typically encountered during
biopharmaceutical manufacturing (Singh et al., 1994;
Al-Rubeai et al., 1995). Bcl-2-mediated anti-apoptosis
engineering was found to be particularly successful
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Figure 6. Fixed-bed reactor cultivation of MG12 cells for 100 days. SEAP production ( ), DNA concentration (#) as well as the modeled
tetraycycline concentration (−−) is shown. The reactor consisted of a 50 ml fixed-bed and a 1000 ml conditioning vessel and was operated
at a dilution rate of 3 ml medium per ml fixed bed per day. This reactor configuration shows the regulatability and the genetic stability of
multicistronic expression unit over an extended cultivation period of 100 days.
and relevant in hybridoma cells since this cell line is
highly sensitive to apoptosis and since strategies to
arrest cell growth of hybridoma cells lead to increased
antibody titers but also to enhanced apoptosis (Suzuki
and Ollis, 1990; Al-Rubeai et al., 1992; Mercille and
Massie, 1994; Takahashi et al., 1994; Itoh et al., 1995;
Singh et al., 1996; Huang et al., 1997; Simpson et
al., 1997; Terada et al., 1997; Fassnacht et al., 1998a,
b; Chung et al., 1998; Mastrangelo and Betenbaugh,
1998; Huang et al., 1997; Terada et al., 1997). Al-
though the overexpression of anti-apoptosis effectors
could neither prevent nor completely block the onset
of apoptosis in hybridoma cell cultures a consensus
finding was that apoptosis was significantly delayed in
bcl-2-overexpressing cultures during the decline phase
(Singh et al., 1996; Chung et al., 1997; Fassnacht et
al., 1998a, b).
However, reports on the effect of Bcl-2-mediated
protection under suboptimal nutrient conditions were
more controversal, reaching from only marginal ef-
fects (Chung et al., 1998) to growth under complete
exhaustion of glutamine (Singh et al., 1996). Re-
cently, Simpson et al. (1998) showed that the pro-
tective effect of Bcl-2 varied in response to medium
deprivation for different essential amino acids, sug-
gesting that apoptosis suppression could be involved in
the down-regulation of non-essential cellular functions
(Simpson et al., 1998). The variety of effects with
respect to protection against apoptosis as well as the
recent controversy whether Bcl-2 expression increases
antibody productivity of hybridoma cells (Itoh et al.,
1995) or not (Fassnacht et al., 1998a) may reside either
in the various cell lines and cell systems used or are a
consequence of clonal variation, effects of integration
sites and expression levels.
Therefore, we regulated gene expression to as-
sess Bcl-2 function in a complete isogenic cellular
background in CHO cell lines. Although high level
expression of Bcl-2 as determined by Western blot
analysis and immunofluorescence microscopy using
human-specific antibodies could be observed in the
absence of the external regulatory stimulus tetracyc-
line, no difference in the decline phase of MG12
populations with respect of the state of Bcl-2 ex-
pression could be detected. Apoptosis assays such as
DNA fragmentation determination and quantification
of casepase 3 using Clontech’s ApoAlert technology
failed to detect apoptosis characteristics in batch cul-
ture before day 14 when the cells enter the decline
phase and where the membrane intact index dra-
matically decreases and the classical DNA laddering
becomes apparent. This result does not necessarily
suggest that Bcl-2 is not protective in CHO cells since
Bcl-2-expressing cells seem to be more robust and
grow to a double final cell density as respective control
populations with repressed Bcl-2 transgene. However,
bcl-2 has previously been shown to be little or not pro-
tective against programmed cell death of NSO cells
(Murray et al., 1996). NSO cells naturally express
high levels of the Bcl-2 homologue Bcl-xL which may
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render Bcl-2 overexpression redundant and therefore
ineffective in the NSO cell background (Murray et al.,
1996). Relatively high Bcl-2 and Bcl-xL expression
levels have also been found in CHO cells (Cotter et
al., unpublished observation) which may explain why
Bcl-2-based metabolic engineering is little protective
against apoptosis of CHO cells grown in batch culture.
Certainly, various reports show that Bcl-2 is able
to delay the onset of apoptosis in CHO cells but induc-
tion of programmed cell death has only been achieved
by severe chemical, genetic, biochemical or viral in-
sults (Balajthy et al., 1997; Chung et al., 1997; He
et al., 1996; Meikrantz et al., 1998; Reynolds et al.,
1996a, b; Zhang et al., 1995). However, such severe
chemical, genetic, biochemical or viral insults are
known to trigger specific cellular repair and survival
programs which may particularly interfere with Bcl-2
protective pathways and could lead to overestimation
of the survival potential of Bcl-2 in batch culture
or normal bioreactor operation. However, we could
show that overexpression of bcl-2 reproducibly allows
CHO cells to grow to double the final cell density in
batch cultures compared to the same cells grown with
repressed bcl-2-encoding expression unit. Despite this
phenomenon which suggest a higher robustness of
CHO cells under bcl-2-expressing conditions, no sig-
nificant difference of apoptosis characteristics could
be detected between the two isogenic cell culture
states. However, Bcl-2-mediated increase of final cell
density of CHO cultures could have positive impact
on industrially relevant production processes since
heterologous protein production is primarily a func-
tion of the viable cell population. Whether higher
overall antibody production of Bcl-2-overexpressing
hybridoma cell lines reported by Itoh et al. (1995)
is based on the same phenomenon remains to be
investigated.
We recently reported a novel metabolic engineer-
ing strategy to arrest CHO cells in G1-phase of the
cell cycle by the overexpression of critical tumor sup-
pressor genes. Despite the complete growth block
arrested CHO populations showed no apoptotic beha-
vior except for overexpression of p53 (Mazur et al.,
1998). Following this observation we included the sur-
vival gene bcl-xL (a homologue of bcl-2) also in a
p27-based tricistronic cytostatic expression unit. In-
terestingly, Bcl-xL-overexpressing CHO cells showed
no enhanced protective properties against apoptosis
but an enhancement in the final heterologous protein
production by a factor up to 3 compared to arres-
ted CHO populations lacking this additional survival
factor (Fussenegger et al., 1998b). Although these
phenomena cannot yet be explained on a mechan-
istic and molecular level, these findings support the
idea that bcl-2 and bcl-xL are not exclusively associ-
ated with the well-established apoptosis pathway. For
example, Minn et al. (1996) demonstrated that over-
expression of the Bcl-2 related protein Bcl-xL induces
tetraploidy, a phenomenon which may correlate with
higher higher heterologous protein production due to
amplification of genetic information.
Although the effects of Bcl-2 overexpression in the
CHO batch cultures reported here are different from
those reported for hybridoma cells, similar protective
effects are found for both cell types in fixed-bed re-
actors as judged by the DNA released into the culture
supernatant. These findings indicate that the effect of
Bcl-2 overexpression depends not only on the cell line
but also on the cultivation conditions used. This latter
notion is particularly supported by direct comparison
of relative Bcl-2-mediated effects on CHO populations
grown in batch culture and in the fixed-bed reactor.
Whereas in the batch cultures Bcl-2 overexpression
resulted in higher final cell densities and almost no
apoptosis-protective effects, lower DNA release indi-
cated lower death rate in fixed-bed reactor configura-
tions. Since the glucose and glutamine consumption
rates were identical for Bcl-2 expressing (-tet) and
Bcl-2 repressing steady-states (+tet) in the fixed-bed
reactor, it can be assumed that the cell density within
the fixed-bed remained largely unchanged. However,
the molecular basis for such diverse Bcl-2-mediated
effects under different culture conditions remains to
be investigated.
Although fixed-bed reactors are the reactor type of
choice for extended high density cell cultures, the ge-
netic characterization of the cell line is impaired by
the limited access to the cells for off-line analysis.
Multicistronic expression technology, which allows
strict linkage of the metabolic engineering effector
to a secreted reporter gene proved extremely useful
to monitor expression of the effector transgene bcl-2.
Also, multicistronic expression technology could be
shown to be very stable over extended culture periods
and still retain full regulatability by tetracycline. This
high genetic stability would allow the use of regulated
multigene metabolic engineering for extended indus-
trially relevant production processes as has recently
been developed, for example, for cytostatic production
technology (Fussenegger et al., 1997, 1998b; Mazur et
al., 1998).
Regulated multigene metabolic engineering showed
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the potential to assess genetic targets for metabolic
engineering in a pure isogenic background. Anti-
apoptosis engineering is not only important for main-
taining high viability when grown in reactors but is
gaining increasing importance for in vivo cultures of
primary cell lines for use in tissue culture and gene
therapy. A combined effect of bcl-2 to suppress ap-
optosis and to increase the final cell density would
therefore greatly stimulate the use of bcl-2 for various
applied bioprocesses.
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